| Biosimilars and follow-on biologics. | |
| | |
MedLine Citation:
|
PMID: 19402802 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This was the Center for Business Intelligence's 2nd Annual Summit on Biosimilars. The participants included industry, government, academics and private professionals involved in the myriad issues of biosimilars. Its purpose was to present a dialogue to evaluate the legal, regulatory and economic landscape in the USA and abroad and prepare for the anticipated US legislation that will enable the entry of biosimilars. Another conference will be held in September to discuss the various pending biosimilar bills in more detail or the new law, if passed. |
| | |
Authors:
|
Joseph P Fuhr |
Publication Detail:
|
Type: Congresses |
Journal Detail:
|
Title: Expert review of pharmacoeconomics & outcomes research Volume: 9 ISSN: 1744-8379 ISO Abbreviation: Expert Rev Pharmacoecon Outcomes Res Publication Date: 2009 Apr |
Date Detail:
|
Created Date: 2009-04-30 Completed Date: 2009-08-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101132257 Medline TA: Expert Rev Pharmacoecon Outcomes Res Country: England |
Other Details:
|
Languages: eng Pagination: 149-50 Citation Subset: IM |
Affiliation:
|
Widener University, One University Place, Chester, PA 19013, USA. jpfuhr@widener.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Canada Drugs, Generic* Legislation, Drug / trends* Therapeutic Equivalency* United States United States Federal Trade Commission United States Food and Drug Administration World Health Organization |
| Chemical | |
Reg. No./Substance:
|
0/Drugs, Generic |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Research and action: toward good quality of life and equity in health.
Next Document: NICE at 10 years: new challenges ahead.